{"id":1817,"date":"2012-08-06T21:24:00","date_gmt":"2012-08-07T01:24:00","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=1817"},"modified":"2012-08-06T21:24:00","modified_gmt":"2012-08-07T01:24:00","slug":"cytomedix-share-price-surges-after-coverage-determination-granted-by-cms-cmxi","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/cytomedix-share-price-surges-after-coverage-determination-granted-by-cms-cmxi-1817","title":{"rendered":"Cytomedix Share Price Surges After Coverage Determination Granted by CMS (CMXI)"},"content":{"rendered":"

Cytomedix (OTC: CMXI) staged a huge rally in today\u2019s trading session after informing the public that the Center for Medicare & Medicaid Services (CMS) granted Coverage<\/a> with Evidence Development (CED) for the Cytomedix AutoloGel products.<\/p>\n

Today’s press release mentions that the Centers for Medicare & Medicaid Services issued\u00a0a National Coverage Determination (NCD) on August 2, 2012,\u00a0for autologous, blood-derived products used in the treatment of chronic, non-healing wounds. The decision reverses nearly 20 years of non-coverage for autologous, platelet-rich plasma (PRP) treatments. The journey is far from over, as the CMS granted coverage to AutoloGel under its Coverage with CED program. The CMS noted in its decision to award the determination of coverage that patients must be enrolled in a clinical research study in order to receive the benefits of coverage. However, this does mean that AutoloGel is currently the only FDA-approved product for autologous PRP treatment.<\/p>\n

Cytomedix opened today\u2019s trading session at a share price of $1.54. The stock quickly surged to a share price of $1.77 before 10:00 a.m. and eventually closed at $1.64, or 30.2% higher than its closing price on Friday. With 532,208 shares exchanging hands, Cytomedix also traded at a higher volume than its previous session.<\/p>\n

With today\u2019s positive performance, Cytomedix now has a year-to-date gain of 45.1% in share price. The stock steadily rallied from New Year\u2019s Day until May 15, 2012, when Cytomedix peaked at an annual high of $2.28 per share. Cytomedix had been declining since May 31, 2012, until the stock started to show signs of a comeback on July 3, 2012.<\/p>\n

Stockpromoters.com lists The Stock Wizards and Penny Trader Publisher as the promoters for Cytomedix. Both promotions are from today and compensations are not mentioned. On Twitter, @pennystock24 mentioned that Penny Stock Wizards<\/a> and Penny Trader COM<\/a>\u00a0promoted Cytomedix today.<\/p>\n

Other notable headlines for Cytomedix include:<\/p>\n